Ginkgo Bioworks Holdings annual total liabilities
2020
2021
2022
2023
2024
2025
Ginkgo Bioworks Holdings Total Liabilities Growth & History (DNA)
Ginkgo Bioworks Holdings's total liabilities was $611.1M for fiscal 2025.
View full Ginkgo Bioworks Holdings company overviewGinkgo Bioworks Holdings annual total liabilities history
| Fiscal year | Period ended | Total liabilities | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $611.1M | −$50.3M | −7.60% |
| 2024 | 2024-12-31 | $661.4M | $93.2M | +16.40% |
| 2023 | 2023-12-31 | $568.2M | −$234.9M | −29.25% |
| 2022 | 2022-12-31 | $803.0M | $299.4M | +59.46% |
| 2021 | 2021-12-31 | $503.6M | $298.5M | +145.54% |
| 2020 | 2020-12-31 | $205.1M | — | — |
Ginkgo Bioworks Holdings quarterly total liabilities
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Total liabilities | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $569.8M | −$48.3M | −7.81% |
| Q1 2026 | 2026-03-31 | $589.9M | −$56.1M | −8.69% |
| Q4 2025 | 2025-12-31 | $611.1M | −$50.3M | −7.60% |
| Q3 2025 | 2025-09-30 | $629.4M | −$53.6M | −7.84% |
| Q2 2025 | 2025-06-30 | $618.1M | −$174.1M | −21.98% |
| Q1 2025 | 2025-03-31 | $646.0M | $51.5M | +8.67% |
| Q4 2024 | 2024-12-31 | $661.4M | $93.2M | +16.40% |
| Q3 2024 | 2024-09-30 | $682.9M | −$90.8M | −11.73% |
| Q2 2024 | 2024-06-30 | $792.2M | $3.8M | +0.48% |
| Q1 2024 | 2024-03-31 | $594.5M | −$215.1M | −26.57% |
| Q4 2023 | 2023-12-31 | $568.2M | −$234.9M | −29.25% |
| Q3 2023 | 2023-09-30 | $773.7M | $342.8M | +79.53% |
| Q2 2023 | 2023-06-30 | $788.4M | $361.3M | +84.57% |
| Q1 2023 | 2023-03-31 | $809.6M | $365.9M | +82.48% |
| Q4 2022 | 2022-12-31 | $803.0M | $299.4M | +59.46% |
| Q3 2022 | 2022-09-30 | $431.0M | −$101.7M | −19.09% |
| Q2 2022 | 2022-06-30 | $427.2M | $172.2M | +67.55% |
| Q1 2022 | 2022-03-31 | $443.7M | $293.5M | +195.51% |
| Q4 2021 | 2021-12-31 | $503.6M | $298.5M | +145.54% |
| Q3 2021 | 2021-09-30 | $532.6M | — | — |
| Q2 2021 | 2021-06-30 | $255.0M | — | — |
| Q1 2021 | 2021-03-31 | $150.1M | — | — |
| Q4 2020 | 2020-12-31 | $205.1M | — | — |
Ginkgo Bioworks Holdings total liabilities trends
Over the last five fiscal years, Ginkgo Bioworks Holdings's total liabilities increased from $205.1M to $611.1M, a change of $406.0M. The latest reported quarter, Q2 2026, shows $569.8M.
About the metric
What total liabilities mean
Total liabilities are all obligations reported on a company’s balance sheet, including debt, accounts payable, accrued expenses, deferred revenue, lease liabilities, and other current and long-term obligations.
Calculation and source
SEC-reported and calculated total liabilities
TickerStat uses total liabilities reported in company SEC filings when available. Otherwise, it calculates total liabilities as aligned total assets minus total equity for the same balance-sheet date. Total liabilities should not be confused with interest-bearing debt. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Ginkgo Bioworks Holdings source filings ↗Community posts
Ginkgo joins a federally backed RNA-manufacturing project worth up to $17.5 million
Ginkgo Bioworks ($DNA) received a subcontract worth up to $17.5 million to participate in an ARPA-H program focused on RNA manufacturing. Waterfall Scientific is the prime contractor. The project, called ESCALATOR, is intended to combine co ...